VANCOUVER, British Columbia–(BUSINESS WIRE)–#BC–Microbiome Insights, Inc., a leading provider of microbiome DNA
sequencing and bioinformatic analysis, today announced the appointment
of Mr. Don Enns as an independent member to its Board of Directors. Enns
has been a senior executive and leader in the life sciences industry for
over 30 years and brings significant company-building experience focused
on providing lab testing, analytical, development, and manufacturing
services to the environmental, pharmaceutical, biotechnology, and food
industries globally.
“Don is a very experienced and highly-regarded business leader in the
life sciences industry, and is known for building value in companies,”
says Mr. Malcolm Kendall, Microbiome Insights’ Chief Executive Officer.
“We are delighted to have him join our Board of Directors. His
operational and finance expertise, as well as his strategic insights are
important for the company at this stage in its growth.”
Enns is currently the Vice President and Head of Global Drug Delivery at
Evonik Industries, one of the world’s leading specialty chemicals
companies, with over €14 billion in annual revenue. He joined Evonik in
2016 with its acquisition of Transferra Nanoscience, where he was
President and CEO. Transferra Nanosciences provided chemistry
manufacturing and products to pharmaceutical and biotechnology
companies, specializing in the development and manufacture of complex
drug delivery systems using lipid nanoparticle science. Prior to this,
Enns was President and CEO of CANTEST Ltd., a BC-headquartered company
providing professional analytical and clinical services in support of
the environmental, pharmaceutical, biotechnology, and food safety
industries. CANTEST Ltd. was acquired by Maxxam Analytics International
Corp., an OMERS owned company, in 2009.
Enns says, “Better understanding the microbiome represents a not only a
significant business opportunity but also a paradigm shift in the way we
monitor and treat the health of patients. I am excited to be part of
Microbiome Insights and look forward to seeing the contribution we can
make to this exciting field.”
The appointment of Enns coincides with the end of Dr. Pieter Cullis’s
tenure as a member of the Board of Directors for Microbiome Insights.
Cullis leaves to become Scientific Director of the newly established
NanoMedicines Innovation Network (NMIN), a research centre focused on
expanding Canada’s position as a leader in nanomedicines R&D. Cullis was
a founding board member and served as a director for over four years.
The company is grateful for his service and wishes him success as he
guides this exciting new national centre of excellence.
About Microbiome Insights, Inc.
Microbiome Insights, Inc. is a global provider of end-to-end services
for microbiome DNA sequencing and state-of-the-art bioinformatic
analysis. Based in Vancouver, Canada, the company’s customized suite of
services enables researchers and clinicians to include microbiome
analysis in studies across a range of human, animal, agricultural, and
environmental applications. The multidisciplinary team of researchers
and knowledge leaders at the company’s helm provide access to decades of
expertise in traditional sciences such as ecology, microbiology,
infectious diseases, and genetics. Microbiome Insights’ award-winning
team is committed to providing clients with fast, dependable,
cost-effective results. Learn more: microbiomeinsights.com.
Contacts
Kristina Campbell
KC Microbiome Communications Group, Inc.
kristina@kcmicrobiome.com
778-350-5993